Ra Pharmaceuticals (NASDAQ:RARX) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Several other analysts have also recently weighed in on the company. Zacks Investment Research cut Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. Raymond James upgraded Ra Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $28.00 price target on the stock in a report on Wednesday. ValuEngine upgraded Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Credit Suisse Group boosted their price target on Ra Pharmaceuticals from $14.00 to $17.00 and gave the stock an “outperform” rating in a report on Tuesday, August 7th. Finally, BMO Capital Markets began coverage on Ra Pharmaceuticals in a report on Friday, July 20th. They set an “outperform” rating and a $20.00 price target on the stock. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Ra Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $19.00.

Ra Pharmaceuticals stock opened at $15.29 on Friday. Ra Pharmaceuticals has a 12-month low of $4.78 and a 12-month high of $19.43. The stock has a market capitalization of $585.03 million, a price-to-earnings ratio of -6.34 and a beta of 1.42.

Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Wednesday, August 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.01. On average, equities research analysts forecast that Ra Pharmaceuticals will post -2.14 EPS for the current year.

Large investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC lifted its stake in shares of Ra Pharmaceuticals by 817.8% in the first quarter. Cubist Systematic Strategies LLC now owns 19,999 shares of the company’s stock worth $106,000 after acquiring an additional 17,820 shares during the period. Gabelli Funds LLC acquired a new position in shares of Ra Pharmaceuticals in the second quarter worth approximately $120,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Ra Pharmaceuticals in the first quarter worth approximately $128,000. Nisa Investment Advisors LLC acquired a new position in shares of Ra Pharmaceuticals in the second quarter worth approximately $157,000. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of Ra Pharmaceuticals by 50.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 32,800 shares of the company’s stock worth $175,000 after acquiring an additional 11,000 shares during the period. Institutional investors own 72.30% of the company’s stock.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Article: Trading Penny Stocks

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.